ASCO GU Symposium 2026

Congress coverage by Medthority

Last updated: 27th Feb 2026

Published: 27th Feb 2026

Gain insights into the practice-changing conversations happening at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium with our selection of key highlights. Discover how emerging data in prostate cancer (PC), muscle-invasive bladder cancer (MIBC), and non–muscle-invasive bladder cancer (NMIBC) are shaping the next wave of therapeutic strategies, from pivotal phase 3 trials and biomarker-driven approaches to real-world evidence and innovative treatment paradigms.

Neal Shore, Ashish Kamat, and Thomas Powles

NMIBC congress updates

Breaking data and expert insights

Audience listening to speaker in neon light

ASCO GU 2026: Prostate cancer news

Latest evidence and real-world insights in mPC

Digital image of a myeloblast, an immature precursor cell of granulocytes found in bone marrow.

Cabazitaxel adds no benefit in VHR prostate cancer

At ASCO GU, Karim Fizazi reports PEACE-2 results showing cabazitaxel adds no benefit to ADT and radiotherapy in very high-risk prostate cancer.

Developed by EPG Health for Medthority, independently of any sponsor.

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information

Name

Email address

Specialty

By providing your email address, you are opting in to receive our monthly newsletter.

Opt-in: By selecting this box, I consent to receiving marketing communications and information about Medthority's resources by email.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event